B cell-targeted therapies in Sjogren's syndrome

被引：31
|
作者：
Tobon, Gabriel J.
Pers, Jacques Olivier
Youinou, Pierre
Saraux, Alain
机构：
[1] CHU Brest, Serv Rhumatol, F-29285 Brest, France
[2] Univ Bretagne Occidentale, EA2216, IFR148, Brest, France
来源：
AUTOIMMUNITY REVIEWS | 2010年 / 9卷 / 04期
关键词：
Sjogren's syndrome; B cell; Rituximab; Epratuzumab; BAFF; SALIVARY-GLANDS; RITUXIMAB; BAFF; LYMPHOCYTES; RECEPTOR; CD22; EFFICACY; BLOOD; OVEREXPRESSION; CLASSIFICATION;
D O I：
10.1016/j.autrev.2009.08.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Sjogren's syndrome (SS) or autoimmune epithelitis is characterized by focal lymphocytic infiltrates surrounding the tubular epithelium of exocrine glands and by overactivity of the B-cell population. Although T cells were long considered the main effectors in SS, recent findings indicating a key role for B cells have prompted studies of treatments designed to deplete the B-cell population. Among molecules that can be targeted to achieve B-cell depletion, CD20 and CD22 are surface antigens expressed specifically by B lymphocytes; and the cytokine B-cell-activating factor belonging to the TNF family (BAFF) is a TNF receptor ligand involved in B-cell differentiation, survival, and activation. The aim of this review is to discuss the clinical outcomes of SS patients treated with B-cell depletion. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码：224 / 228
页数：5
相关论文
共 50 条
  • [41] Next Generation SMART DRUGS: Aptamer-Based Cell-Targeted Cancer Therapies
    Dassie, Justin P.
    Hernandez, Luiza I.
    Thomas, Gregory S.
    Long, Matthew E.
    Rockey, William M.
    Howell, Craig A.
    Hernandez, Frank J.
    Liu, Xiu Y.
    Allen, Lee A.
    Giangrande, Paloma H.
    MOLECULAR THERAPY, 2014, 22 : S96 - S97
  • [42] Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis
    Baker, David
    Jacobs, Benjamin M.
    Gnanapavan, Sharmilee
    Schmierer, Klaus
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 19 - 25
  • [43] B Lymphocytes in Sjogren's syndrome
    Pers, J. -O.
    Le Pottier, L.
    Devauchelle, V.
    Saraux, A.
    Youinou, P.
    REVUE DE MEDECINE INTERNE, 2008, 29 (12): : 1000 - 1006
  • [44] Development of an Antigen Delivery System for a B Cell-Targeted Vaccine as an Alternative to Dendritic Cell Targeted Vaccines
    Shimizu, Taro
    Kawaguchi, Yoshino
    Ando, Hidenori
    Ishima, Yu
    Ishida, Tatsuhiro
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2022, 70 (05) : 341 - 350
  • [45] Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome
    DeVita, S
    Boiocchi, M
    Sorrentino, D
    Carbone, A
    Avellini, C
    Dolcetti, R
    Marzotto, A
    Gloghini, A
    Bartoli, E
    Beltrami, CA
    Ferraccioli, G
    ARTHRITIS AND RHEUMATISM, 1997, 40 (02): : 318 - 331
  • [46] Autoimmune B Cell Repertoire in a Mouse Model of Sjogren's Syndrome
    Saez Moya, Manuel
    Gutierrez-Cozar, Rebeca
    Punet-Ortiz, Joan
    Rodriguez de la Concepcion, Maria Luisa
    Blanco, Julia
    Carrillo, Jorge
    Engel, Pablo
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [47] Therapeutic Potential for B-Cell Modulation in Sjogren's Syndrome
    Mariette, Xavier
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2008, 34 (04) : 1025 - +
  • [48] B-cell lymphoma in patients with Sjogren's syndrome.
    Lakshminarayanan, S
    Waterman, J
    Parke, A
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S328 - S328
  • [49] B cell-targeted therapy in diseases other than rheumatoid arthritis
    Looney, RJ
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 25 - 28
  • [50] Innate Immunity and Biological Therapies for the Treatment of Sjogren's Syndrome
    Srivastava, Amrita
    Makarenkova, Helen P.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (23) : 1 - 45
12345